Immunotherapy in head and neck squamous cell carcinoma: An updated review

Immunotherapy in head and neck squamous cell carcinoma: An updated review

Squamous cell cancer of the head and neck (HNSCC) is the sixth most common cancer and is associated with significant morbidity and mortality. The tumor microenvironment for HNSCC is a complex interplay of immune cells, stromal cells, and cytokines amongst others. Immunotherapy acts as an effective a...

Full description

Bibliographic Details
Main Authors:	K. Parmar, A. Mohamed, E. Vaish, R. Thawani, J. Cetnar, K.Z. Thein
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Series:	Cancer Treatment and Research Communications
Subjects:	Immunotherapy Pembrolizumab Nivolumab Head and neck squamous cell carcinoma Tumor microenvironment Immune and stromal cells
Online Access:	http://www.sciencedirect.com/science/article/pii/S246829422200140X

Similar Items

Immunotherapy and its advances in the management of head-and-neck cancer
by: Sajad Ahmad Buch, et al.
Published: (2019-01-01)

Evolving role of immunotherapy in head-and-neck cancers: A systemic review
by: Raajit Chanana, et al.
Published: (2018-01-01)

Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma
by: Shaokun Liu, et al.
Published: (2024-01-01)

Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas
by: Görkem Eskiizmir
Published: (2015-09-01)

Global research trends in immunotherapy for head and neck neoplasms: A scientometric study
by: Zhou Jiang, et al.
Published: (2023-04-01)

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab
by: Daisuke Nishikawa, et al.
Published: (2018-11-01)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Bruno Chauffert, et al.
Published: (2023-01-01)

Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis
by: Dongmei Ye, et al.
Published: (2024-03-01)

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
by: Hyera Kim, et al.
Published: (2020-08-01)

Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy
by: Xinhai Zhang, et al.
Published: (2020-12-01)

Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience
by: Yue (Jennifer) Du, et al.
Published: (2023-09-01)

Biomarkers predictive of response to pembrolizumab in head and neck cancer
by: David G. Pfister, et al.
Published: (2023-03-01)

Basaloid squamous cell carcinoma of the head and neck: Our experience
by: Jaimanti Bakshi, et al.
Published: (2020-01-01)

Human Mesenchymal Stromal Cells Do Not Cause Radioprotection of Head-and-Neck Squamous Cell Carcinoma
by: Alexander Rühle, et al.
Published: (2022-07-01)

Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
by: Piero Giuseppe Meliante, et al.
Published: (2023-02-01)

Recurrent and Metastatic Head and Neck Cancer: A Paradigm Shift?
by: Leonor Abreu Ribeiro, et al.
Published: (2020-09-01)

Recent advances and prospect in immune microenvironment and its mechanisms of function in head and neck squamous cell carcinoma
by: ZHANG Shaoqiu, YAN Li, LI Ruichen, ZHAO Yang, WANG Xiaoshen, YANG Xuguang, ZHU Yi
Published: (2023-06-01)

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab
by: Suzuki S, et al.
Published: (2022-11-01)

Immunotherapy in Head and Neck Squamous Cell Cancer
by: Nerina Denaro, et al.
Published: (2018-12-01)

Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis
by: Hsiang-Fong Kao, et al.
Published: (2022-11-01)

Exosomes in Head and Neck Squamous Cell Carcinoma
by: Cheng Xiao, et al.
Published: (2019-09-01)

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis
by: Denaro N, et al.
Published: (2021-05-01)

PLODs: Novel prognostic biomarkers and potential immunotherapy targets for head and neck squamous cell carcinoma
by: Siming Gong, et al.
Published: (2023-02-01)

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial
by: Andrea Botticelli, et al.
Published: (2020-04-01)

The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment
by: Ye Zhang, et al.
Published: (2023-05-01)

Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
by: Chenhang Yu, et al.
Published: (2022-08-01)

Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
by: Kohei Okuyama, et al.
Published: (2023-05-01)

An immune‐related seven‐lncRNA signature for head and neck squamous cell carcinoma
by: Yue Chen, et al.
Published: (2021-04-01)

Exosomes in head and neck cancer. Updating and revisiting
by: Samuel Rodríguez Zorrilla, et al.
Published: (2019-01-01)

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy
by: Habib Sadeghirad, et al.
Published: (2023-04-01)

DISEASE RECURRENCE PREDICTORS FOR PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA
by: Yuniardini S. Wimardhani, et al.
Published: (2015-06-01)

Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients
by: Arutha Kulasinghe, et al.
Published: (2021-01-01)

Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
by: Xuanli Xu, et al.
Published: (2021-11-01)

Immune-related lncRNA classification of head and neck squamous cell carcinoma
by: Ruoyan Cao, et al.
Published: (2022-01-01)

Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma
by: Xia Li, et al.
Published: (2021-05-01)

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck
by: Hideki Tanaka, et al.
Published: (2023-11-01)

Comprehensive investigation into the influence of glycosylation on head and neck squamous cell carcinoma and development of a prognostic model for risk assessment and anticipating immunotherapy
by: Heng Ma, et al.
Published: (2024-03-01)

Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
by: Anagha Gogate, et al.
Published: (2023-07-01)

The Role of Deubiquitinating Enzyme in Head and Neck Squamous Cell Carcinoma
by: Shengjian Jin, et al.
Published: (2022-12-01)

Epidemiology of head and neck squamous cell carcinoma in birjand city, between 2008 and 2017
by: Leili Alizadeh, et al.
Published: (2019-07-01)